Kazia Therapeutics Limited

Kazia Therapeutics Limitedverified

KZIA

Price:

$0.2411

Market Cap:

$8.54M

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.[Read more]

Industry

Biotechnology

IPO Date

1999-01-06

Stock Exchange

NASDAQ

Ticker

KZIA

The PE Ratio as of June 2024 (TTM) for Kazia Therapeutics Limited (KZIA) is -0.65

According to Kazia Therapeutics Limited’s latest financial reports and current stock price. The company's current PE Ratio is -0.65. This represents a change of -67.25% compared to the average of -1.98 of the last 4 quarters.

Kazia Therapeutics Limited (KZIA) Historical PE Ratio (quarterly & annually)

How has KZIA PE Ratio performed in the past?

The mean historical PE Ratio of Kazia Therapeutics Limited over the last ten years is -21.24. The current -0.65 PE Ratio has changed 206.01% with respect to the historical average. Over the past ten years (40 quarters), KZIA's PE Ratio was at its highest in in the September 2017 quarter at 217.73. The PE Ratio was at its lowest in in the December 2012 quarter at -98.89.

Quarterly (TTM)
Annual

Average

-21.24

Median

-3.24

Minimum

-183.56

Maximum

-1.55

Kazia Therapeutics Limited (KZIA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kazia Therapeutics Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 6.28%

Maximum Annual PE Ratio = -1.55

Minimum Annual Increase = -98.22%

Minimum Annual PE Ratio = -183.56

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.55-52.59%
2022-3.27-98.22%
2021-183.566.28%
2020-2.8836.65%
2019-2.11-34.23%
2018-3.2056.20%
2017-2.05-42.43%
2016-3.56-48.91%
2015-6.97112.81%
2014-3.28-83.62%

Kazia Therapeutics Limited (KZIA) Average PE Ratio

How has KZIA PE Ratio performed in the past?

The current PE Ratio of Kazia Therapeutics Limited (KZIA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-62.79

5-year avg

-38.67

10-year avg

-21.24

Kazia Therapeutics Limited (KZIA) PE Ratio vs. Peers

How is KZIA’s PE Ratio compared to its peers?

Kazia Therapeutics Limited’s PE Ratio is less than CytomX Therapeutics, Inc. (6.40), greater than Assembly Biosciences, Inc. (-1.59), greater than Ocular Therapeutix, Inc. (-6.29), less than Spero Therapeutics, Inc. (2.90), less than Achilles Therapeutics plc (-0.56), greater than SELLAS Life Sciences Group, Inc. (-1.33), greater than NLS Pharmaceutics AG (-0.72), greater than Mereo BioPharma Group plc (-79.27), less than Aravive, Inc. (-0.04), greater than Day One Biopharmaceuticals, Inc. (-5.55), greater than ZIVO Bioscience, Inc. (-3.10), greater than RenovoRx, Inc. (-2.54), less than Pasithea Therapeutics Corp. (-0.33), less than Quoin Pharmaceuticals, Ltd. (-0.15), greater than ARCA biopharma, Inc. (-8.84), less than Bionomics Limited (0), greater than OKYO Pharma Limited (-4.64), greater than Candel Therapeutics, Inc. (-5.25), greater than Anebulo Pharmaceuticals, Inc. (-5.68), less than Cingulate Inc. (-0.13), greater than Nurix Therapeutics, Inc. (-7.12), greater than Seer, Inc. (-1.30), greater than Quantum-Si incorporated (-2.02), greater than HCW Biologics Inc. (-1.39), greater than MediciNova, Inc. (-7.64),

Build a custom stock screener for Kazia Therapeutics Limited (KZIA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kazia Therapeutics Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kazia Therapeutics Limited (KZIA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kazia Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Kazia Therapeutics Limited's PE Ratio?

How is the PE Ratio calculated for Kazia Therapeutics Limited (KZIA)?

What is the highest PE Ratio for Kazia Therapeutics Limited (KZIA)?

What is the 3-year average PE Ratio for Kazia Therapeutics Limited (KZIA)?

What is the 5-year average PE Ratio for Kazia Therapeutics Limited (KZIA)?

How does the current PE Ratio for Kazia Therapeutics Limited (KZIA) compare to its historical average?